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ABSTRACT 
To study fungal infections such as Mucormycosis, Aspergillosis, Candidiasis, Cryptococcosis associated with Covid-19. 
A detailed study was done with the information gathered from the articles in specified databases, online sources, and online published materials to 
have current details of the situation of fungal infections in covid patients. 
Fungal infections were seen among covid-19 patients mostly due to opportunistic fungal pathogens such as Mucor, Candida, Aspergillus, and 
Cryptococcus. The reason behind rising opportunistic fungal infections among covid-19 patients may be the immunocompromised host. The most 
common species responsible for fungal infections in covid-19 were noticed to be of genus Mucor, A. flavus, and A. fumigatus species of genus 
Aspergillus, C. albicans species of genus Candida, C. neoformans, and C. gattii species of genus Cryptococcus. 
Patients suffering or recovered from covid-19 are now facing numerous Secondary Infections. The majority of secondary infections associated with 
covid-19 are Fungal Infections. Mucormycosis, candidiasis, aspergillosis, cryptococcosis as opportunistic infections are seen widely in the covid-19 
treated patients. Rapid progression of such fungal infections is required to be controlled by early diagnosis of infection and by identifying the 
underlying risk parameters. Protocols for disease management will be beneficial too. 
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INTRODUCTION 
The Global Popularity of covid-19 and the possibility of occurrence of 
Fungal Co-infections has become an emergency worldwide. Just like 
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe 
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is in charge 
of lower respiratory infection and can cause Acute Respiratory 
Distress Syndromes (ARDS). Besides this, diffuse alveolar damage with 
severe inflammatory secretion, covid-19 patients always has 
immunosuppression with a decrease in CD4-T and CD8-T cells. 
Critically ill patients, especially the patients who are admitted to the 
intensive care unit (ICU) and require mechanical ventilation, or having 
a longer duration of hospital stay, are more likely to develop fungal co-
infections. Hence, it is significant to observe that covid-19 patients can 
further develop fungal infections during the middle and latter stages of 
this disease, especially severely ill ones [1].  
Fungi exist in two forms that are yeast and molds, former is typically a 
single, small and oval structure, whereas the latter consists of 
filamentous strands called hyphae. Fungi responsible for disease-
causing in healthy individuals are considered as a true pathogen, while 
those who develop the disease in immune-suppressed individuals are 
referred to as opportunistic pathogens, which mainly involve species 
of Mucor, Candida, Aspergillus, and Cryptococcus [2]. These four 
opportunistic fungal pathogens are reported to cause infections in 
covid-19 patients too [3]. This article is about the review of these 
pathogens, including the terms black, white, yellow, cream, and green 
fungus, which is the point of discussion nowadays. 
Search criteria 
The selections of articles for the current review were searched from 
specialized databases such as IAS-AJPCR, Elsevier, Pubmed, and 
Cambridge using the keywords. Other selections include articles 
from Springer, information from Internet sources, and Online 
published articles from The Lancet Respiratory Medicine, Medscape, 
and Statpearls. The Keywords utilized for searching include the term 
related to fungal infections and covid patients such as “post covid 
fungal infections” OR “fungal infections in patients recovered or 
suffering from covid-19”. Articles displayed on databases were 
screened manually based on their title. Irrelevant pieces of 
information were excluded and the information on Internet sources 
that were up to date and resembled the present scope information 
was included in the study. Inclusion of study was based on criteria 
as-a) articles from peer-reviewed journals are to be included. b) 
Information from Internet sources should contain the present scope. 
c) Fungal infections that were detected in post covid patients (2020-
21). Articles reviewed were only those which were written in 
English and published till now that is 2021 and the information from 
the internet included were those which resembles with study 
criteria, written in English and contains the latest information 
regarding the topic and filtered for 2020 and 2021. After screening 
and filtration 34 studies met the inclusion criteria and were included 
in the review. The selection strategy followed is portrayed in fig. 1. 
Mucor and mucormycosis  
Mucormycosis, among the many severe secondary infections 
associated with covid-19 have high mortality and rising incidence in 
affected and recovered patients [4]. Mucormycosis is the form of 
Zygormycosis caused by genus Mucor of Phylum Zygomycota which 
is described as a lethal infection mostly occurring in an 
immunocompromised host, patients with uncontrolled Diabetes 
mellitus, with leukemia and lymphoma [5, 6]. Nomenclature of 
mucormycosis is done by its anatomic site localization instead of its 
Mycological Classification that is 1 of 6 forms: (1) Rhino cerebral (2) 
pulmonary (3) cutaneous (4) gastrointestinal (5) disseminated (6) 
uncommon presentations [7]. Fungi gain entry via inhalation into 
the paranasal sinuses and spread to the sphenoid sinus, palate, and 
cavernous sinus [6]. High chances of this infection are in those that 
are on hemodialysis, having a high dose of glucocorticoids, have any 
kind of trauma like burns, have acquired immunodeficiency 
syndrome, hematological malignancy, and those who have gone for 
organ transplantation [4-6]. A recent review says that 8% of covid 
Positive or recovered Patients had secondary bacterial or fungal 
infections during their hospital admission, and also due to the 
widespread use of broad-spectrum antibiotics and Steroids [4]. 
Prevalence and incidence in India  
The incidence of mucormycosis as a post covid secondary infection 
reported from different parts of India till 25th May is shown in table 1.
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Fig. 1: Strategies followed for study selection 
 
Table 1: The list of mucormycosis patients is as per the data shared by union minister of India, Sadananda gowda on May 25 
S. No. State Covid cases till 25th may Mucormycetes cases till 25th Ratio Reference 
1 Andhra Pradesh 1593821 768 1593821:768 [8, 9] 
2 Bihar 692420 215 138484:43 [8, 9] 
3 Chandigarh 58734 83 58734:83 [8, 9] 
4 Chhattisgarh 953209 103 953209:103 [8, 9] 
5 Delhi 1418418 119 1418418:119 [8, 9] 
6 Goa 147861 10 147861:10 [8, 9] 
7 Gujarat 791657 2859 791657:2859 [8, 9] 
8 Haryana 741785 436 741785:436 [8, 9] 
9 Himachal Pradesh 180983 3 180983:3 [8, 9] 
10 J and K 272858 5 272858:5 [8, 9] 
11 Jharkhand 331811 29 331811:29 [8, 9] 
12 Karnataka 2,450,215 481 2450215:481 [8, 9] 
13 Kerala 2365787 36 2365787:36 [8, 9] 
14 Madhya Pradesh 767274 752 383637:376 [8, 9] 
15 Maharashtra 5602019 2770 5602019:2770 [8, 9] 
16 Odisha 703441 15 703441:15 [8, 9] 
17 Pondicherry 96982 2 48491:1 [8, 9] 
18 Punjab 543475 141 543475:141 [8, 9] 
19 Rajasthan 920456 492 230114:123 [8, 9] 
20 Tamil Nadu 1877211 236 1877211:236 [8, 9] 
21 Telangana 556320 744 23180:31 [8, 9] 
22 Tripura 47298 1 47298:1 [8, 9] 
23 Uttar Pradesh 1673785 701 1673785:701 [8, 9] 
24 Uttarakhand 315590 124 157795:62 [8, 9] 
27 Total 25103410 11125 5020682:2225 [8, 9] 
   The Average ratio is 5020682:2225   
 
The table clarifies that on average of every 50, 20,682 covid infected 
persons, there are 2225 Mucor patients. Even the new reported 
Mucor cases are less in number. India still contributes to 45% of the 
new globally reported cases and about 34% of deaths during the 
third week of May 2021 [10]. 
Underlying diseases and risk factors  
The major underlying disease being the risk factor for Mucor 
infection is Diabetes mellitus, followed by Leukemia and organ 
transplantation. However, the alarming threat for the Indian 
population is mucormycosis in an immunocompromised host [11]. 
Several studies claim that the patients on hemodialysis, having a 
high dose of Glucocorticoids, having low phagocyte count, impaired 
phagocyte function, neutropenia are more susceptible to Invasive 
Mucormycosis [6].  
A study claims that in patients with poorly controlled Diabetes mellitus, 
elevated blood glucose levels lead to impaired neutrophil function. In 
Ketoacidosis, the hyperglycemia and acidic pH may be expected to result 
in a defect in the motility and killing activity of neutrophils. As the pH 
becomes acidic, the iron-protein complexes dissociate, which allows for 
the fungal cells to use the increased free iron and initiate growth [6]. 
Furthermore, as covid-19 is life-threatening, affected patients show 
overexpression of inflammatory cytokines and impaired cell-
mediated immunity with decreased T helper cell counts, which 
indicate susceptibility to fungal co-infections [4]. 
Critically ill patients, like those in intensive care units and those who 
require mechanical ventilation or who had longer hospital stays are 
more likely to develop fungal co-infections. Larger steroids use for 
covid management can also suppress the immunity of the patients, 
which makes them more prone to opportunistic fungal infections 
[4]. 
Symptoms of mucormycosis  
• Pain and redness 
around eyes and/or nose 
• Numbness or swelling 
• Fever • Blackish discoloration over the 
bridge of nose/palate Toothache 
• Headache • Loosening of teeth 
• Coughing • Jaw involvement 
• Shortness of breath • Blurred or double vision with pain 
• Bloody vomits • Skin lesion 
• Altered mental status • Thrombosis and necrosis (eschar)  
• Sinusitis–nasal 
blockage or congestion 
• Chest pain 
• Nasal discharge 
(blackish/bloody) 
• Pleural effusion 
• Local pain on the 
cheekbone 
• Haemoptysis 
• One-sided facial pain • Worsening of respiratory symptoms 
[12] 
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Treatment and outcomes  
Diagnosis is dependent upon clinical features, pathological findings, 
and imaging to define the extent of involvement. Early diagnosis and 
timely surgery facilitate disease control. The primary guideline for 
treatment is to correct the responsible cause but it is not possible in 
patients reliant on high dose steroid therapy like in covid-19 [5].  
The two mainstays of treatment are medical treatment with 
amphotericin B and with surgical debridement [5]. Be waiting for 
cultures delays the treatment process; direct positive smears may 
become sufficient for treatment initiation. Hyperbaric oxygen 
therapy and treatment with amphotericin B are adjunct modalities. 
Amphotericin B is fungistatic rather than fungicidal which increases 
its treatment duration [5]. Monitoring of kidney function is 
important due to abnormal nephrotoxic incidence of amphotericin 
B. second-line therapies may be contemplated in case of extensive 
disease [6]. 
Recommended second-line therapy is with echinocandins and 
amphotericin B. Echinocandins in combination with amphotericin B 
add a polyene backbone and the success of therapy increases. Some 
other second-line drugs include triazoles, posaconazole, and 
isavuconazole. Triazoles inhibit the 14-α-demethylation, which 
causes an increase in toxic 14-α-methyl sterols which then alters the 
fungal membrane’s permeability [6]. 
Patients that are intolerant to amphotericin B are given 
posaconazole. Isavuconazole is used in the treatment of Invasive 
Mucormycosis because of its extended spectrum. And thus, it is the 
only antifungal used in the treatment of Invasive Mucormycosis [6]. 
Prognosis depends on multiple factors prompt initiation of 
treatment is an essential element [5]. 
After the confirmation of diagnosis, conservative management is 
initiated for the patient [5]. Identification and treatment of any 
underlying condition help in assuring a fair prognosis [6]. It is 
important to take care of hyperglycemia and ketoacidosis in 
uncontrolled Diabetes mellitus patients. Additionally, tapering 
immunosuppressive therapy plays an additional role in the 
treatment of mucormycosis [6]. 
Aspergillus and aspergillosis  
Co-fungal infections are occurring post-covid-19 and it is reported 
that different species of the following genera are causing it: Candida, 
Cryptococcus, Mucor, and Aspergillus [3]. Aspergillus is one of the 
most common pathogens which cause deadly fungal infections. 
Infection is typically caused by Aspergillus fumigatus (about 90%), 
Aspergillus flavus, Aspergillus nidulans, Aspergillus niger, Aspergillus 
terreus, and Aspergillus versicolor. Nowadays, non-fumigatus 
pathogens have also become frequent causative agents of this. 
Identification of the precise species is important as there are 
variations in antifungal susceptibility profiles of different species, 
and also there are differences in how the different species produce 
their clinical presentations [13]. Various species of Aspergillus are 
present in the environment and most commonly, Aspergillus 
fumigatus is present. They cause a wide range of infections in 
humans like Invasive Pulmonary Aspergillosis (IPA), Chronic 
Pulmonary Aspergillosis (CPA), Allergic Broncho-Pulmonary 
Aspergillosis (ABPA), chronic rhinosinusitis, fungal asthma, and 
Aspergillus bronchitis, etc. Not only this it has been found that up to 
40 % of covid-19 hospitalized patients can develop severe ARDS, 
and therefore become more susceptible to acquire co-infections 
caused by bacteria, viruses, or fungi [14]. Patients with clinical 
symptoms of covid-19, reverse transcription-polymerase chain 
reaction (RT-PCR) test confirmed positive, and those requiring 
intensive care due to developing respiratory insufficiency are at high 
risk for Covid Associated Pulmonary Aspergillosis (CAPA). The entry 
criterion proposed was this: positive RT-PCR for SARS CoV-2 
anytime during 2 w between hospital admission and ICU admission 
and or positive RT-PCR within 72–96 h after ICU admission. CAPA 
might develop during the following weeks, and the risk could be 
further increased for superinfections by anti-IL-6-receptor 
treatment for covid-19 or corticosteroid treatment for underlying 
conditions [14]. 
Association between covid-19 and aspergillosis  
The role of interleukin-10: IL-10 regulates cellular immune 
responses and is therefore involved in various inflammatory 
diseases. The highly elevated level of serum IL-6 and IL-10 can lead 
to disease progression as increased production of IL-10, mediates 
the influx of phagocytic cells, which can limit the extent of local 
tissue destruction of Aspergillus infection. Greater Th-2 (T helper 
type 2) cells responses that are the increase of IL-10 or lesser Th-
1(T helper type 1) cells responses, down-regulate macrophage 
responses, and increase host susceptibility to deadly Aspergillus 
infection [3]. 
The role of interleukin-6: pro-inflammatory cytokines and 
chemokines which are elevated in severe covid-19 patients are 
TNFa, IL-6, IL-10, interleukin-1b, and monocyte chemoattractant 
protein-1. Elevated cytokine levels can lead to lethal complications 
of covid-19. Tissue necrosis and interstitial infiltration with 
macrophage and monocyte in the lung, heart, and gastrointestinal 
mucosa are found in severe covid-19 patients with elevated 
inflammatory cytokines. IL-6 is part of the important cytokines 
among the excessive Cytokines Releasing syndrome (CRS). IL-6 is a 
multi-functional cytokine and it plays an important part in 
protective immunity against Aspergillus. After Aspergillus fumigatus 
infection, there is a significant increase in the amount of IL-6. 
Reduced responsiveness is exhibited of T cells to IL-6 in patients 
with IPA. Covid-19 patients with CRS show excessive IL-6 signaling 
which leads to numerous biological effects such as increasing vessel 
permeability, ARDS, cardiac arrhythmia, and reducing myocardial 
contractility. The patients more vulnerable to Invasive Pulmonary 
Aspergillosis are the non-immune compromised patients with ARDS 
whose prevalence can reach up to 15% of patients. Beneficial 
additions to antiviral therapy are immune modulators. IL-6 blockade 
targets the host immune system that can be effective for covid-19. 
The drug tocilizumab is a recombinant humanized monoclonal anti-
IL-6 receptor antibody. Tocilizumab is hereby approved for patients 
with covid-19 pneumonia, ARDS, and elevated IL-6. There should be 
an early diagnosis of Cytokines Releasing syndrome in covid-19 
patients and not only this. There should be prompt initiation of 
immune-modulatory treatment. The duly intervention of elevated 
serum IL-6 levels in patients can avoid the progression and 
complications of covid-19. But IL-6 can be a double-edged sword, 
tocilizumab can be applied in the treatment of covid-19 as an anti-
IL-6 agent, but it can also potentially cause Aspergillus infection by 
decreasing IL-6 immune response [3]. 
Diagnosis  
Diagnosis of CAPA includes the following:  
1. Galactomannan (GM) detection from Serum/Bronchoalveolar 
Lavage Fluid (BALF)/Endotracheal Aspirates (ETA).  
2. Isolation of Aspergillus species from BALF/ETA/sputa  
3. Serum Beta-d Glucan (BDG) detection. 
4. Detection of Aspergillus Deoxyribonucleic Acid (DNA) by real-time 
Polymerase Chain Reaction (PCR) in blood or respiratory samples. 
This approach may aid in the early institution of antifungal therapy [15]. 
Risk factors  
Significantly, the pathogenesis of IPA differs between neutropenic 
and non-neutropenic patients and those with covid-19, impacting 
clinical presentation, radiological findings, and diagnostic test 
results in the mycology laboratory. Despite these significant 
differences, revised European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group 
and National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) definitions focus mainly on neutropenic 
patients with underlying hematological malignancies and “typical” 
presentation of IPA and have limited applicability and inferior 
performance in non-neutropenic patients who frequently do not 
cover radiological and host criteria, including patients with covid-19. 
Therefore an alternative clinical algorithm is created for diagnosing 
IPA in the ICU setting, which defines putative IPA and is now the 
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standard of care for defining IPA in the ICU, but still, highly reliable 
definitions of IA (Invasive Aspergillosis) are missing (as work on 
improved definitions is still in progress).  
The Rapid development of CAPA a few days after ICU admission 
matches the observation made for influenza-associated pulmonary 
aspergillosis. Risk factors vulnerable to covid-19 patients to develop 
secondary pulmonary aspergillosis are the same as those identified for 
influenza-IPA superinfections. The main risk factors include severe 
lung damage during covid-19, the use of corticosteroids in those with 
ARDS, the widespread use of broad-spectrum antibiotics in ICUs, and 
the presence of comorbidities such as structural lung defects [16]. 
Pulmonary fibrosis can be caused by the cytokine storm activated by 
the viral antigens, harmful effects posed by drugs, high airway 
pressure, and hypoxia-induced acute lung injury secondary to 
mechanical ventilation. While interstitial pulmonary fibrosis per se 
does not lay open to the development of IPA, a small group of these 
covid-19 survivors may require corticosteroid treatment for a long 
time, which may lay them open to CAPA years after the acute phase 
of the viral infection. In cases with ARDS, systemic corticosteroids 
are used to alleviate the immune responses and prevent cytokine 
storms, but they may predispose to developing secondary infections 
at the same time [16]. 
Although there is no detailed information on antibiotic use among 
patients, broad-spectrum antibiotics are assumed to be used in 75% of 
covid-19 patients admitted to ICU. As the human gut microbiome is a 
highly complicated structure of bacteria and fungi, and even the 
bacteria are the most diverse constituents, the intake of antibiotics 
results in the disturbance of microbiome steady-state composition, 
which allows fungi to flourish, and may make the host vulnerable to 
destroying fungal infections once the immune system is impaired [16]. 
Underlying medical conditions may also cause covid-19 patients to 
develop CAPA. Hypertension (17/35; 49%), diabetes (9/35; 26%), 
obesity (8/35; 23%), Chronic Obstructive Pulmonary Disease 
(COPD) (5/35; 14%), heart diseases (5/35; 14%), 
hypercholesterinemia (4/35; 11%), and asthma (3/35; 9%) are the 
most prevalent comorbidities found out yet. While diseases like 
hypertension, coronary heart diseases, and diabetes increase the 
risk of infection. Overall the structural lung damage caused by COPD 
or asthma can particularly put patients at risk to develop IPA [16]. 
Antifungal treatment strategies  
The clinical impression, or a proven diagnosis, of Aspergillus co-
infection, should initiate empiric or targeted antifungal therapy, 
respectively, even though its effectiveness is not established. Many 
cases survived their infection and those dying lead to multi-organ 
failure and sepsis. International treatment guidelines suggest 
triazoles voriconazole or isavuconazole as the first-line treatment of 
IA. The emergence of multi-triazole resistance in A. fumigatus 
challenges the effectiveness of triazoles in the successful treatment 
of IPA, specifically in areas of high occurrence, and their use in such 
cases is associated with an increased death rate. Triazole hostility in 
A. fumigatus is causally linked to the use of triazole compounds that 
are structurally similar to those used in medical practice, as 
agricultural fungicides, or less commonly to long-term triazole use in 
individual patients. The early process of resistance typically affects 
azole näive patients and is distinguished by increased Minimum 
Inhibitory Concentrations (MIC) of itraconazole, voriconazole, 
posaconazole, and isavuconazole. These emphasize the significance 
of Antifungal Susceptibility Testing (AFST) either through 
phenotypic or genotypic methods to determine triazole hostility, 
which will help direct the choice of treatment. Although the cultures 
are well known to have a poor diagnostic susceptibility, the ability to 
culture Aspergillus species will allow for the establishment of MICs 
for triazoles. Recently, a four-well triazole resistance screening plate 
was confirmed for A. fumigatus, which can be useful in laboratories 
that cannot perform the suggested broth microdilution methods for 
AFST. Genotypic testing that uses molecular assays has also been 
tested to detect Aspergillus species and the common mutations 
linked with triazole hostility directly from clinical samples, which 
will allow for the rapid detection of a marker of hostility and guide 
treatment options. Many patients received a triazole-based AFT 
regimen either alone or in combination with an echinocandin or 
liposomal amphotericin B. Only a few cases reported sensitivity 
results based on either phenotypic testing and/or the detection of 
common mutations associated with triazole resistance using 
molecular techniques. Others have been reported as being caused by 
the resistance of Aspergillus fumigatus to triazole. All of which were 
confirmed to have the cyp51ATR34L98H mutation. Knowledge of 
the local epidemiology of triazole resistance is significant to help 
guide the choice of therapy while awaiting sensitivity results. It has 
been suggested that for areas with triazole hostility rates of>10%, 
voriconazole-echinocandin combination therapy or liposomal 
amphotericin B should be used as the initial therapy. However, in 
many countries, there are no inspection systems in place to detect 
the occurrence of triazole hostility in A. fumigatus, which is known 
to be the most common Aspergillus species causing IA, as it has also 
been noted in the CAPA cases reported to date [15]. 
It was reported that prophylactic aerosolized liposomal amphotericin-
B was administered to all covid-19 patients on mechanical ventilation 
in critical care after they found a group of CAPA cases, among which 
few were proven. Antifungal prophylaxis formed part of the 
multifaceted management of this cluster, which also included the GM 
screening of serum and BALF twice a week if and when a 
bronchoscopy was performed. HEPA filters were also installed in their 
critical care unit. The logic for prospective trials is required to be 
determined to accept whether antifungal prophylaxis in severe covid-
19 cases is indicated. A clinical trial of posaconazole prophylaxis for 
the avoidance of pulmonary aspergillosis in patients with severe 
influenza (NCT03378479) is currently ongoing and this will give data 
on the efficacy of this approach at least for influenza [15]. 
New antifungal agents with a novel mechanism of action are in the pipeline 
to deal with the problem of antifungal hostility, which endangers the 
efficacy of the few agents currently being used to cure invasive fungal 
disease. Clinical trials are ongoing for new antifungal agents, namely, 
ibrexafungerp (NCT03672292), olorofim (NCT03583164), and 
fosmanogepix (NCT04240886). Ibrexafungerp, which is structurally the 
same as echinocandins, hinder fungal-1,3-glucan synthase with activity 
against triazole-resistant Aspergillus sp. Olorofim and fosmanogepix have 
different novel targets, which are fungal dihydroorotate dehydrogenase, a 
significant enzyme in the fungal DNA synthesis, and the obstruction of 
fungal enzyme Gwt1 inactivating change of mannoproteins, which is a 
significant component in maintaining fungal cell wall integrity, 
respectively. All three agents have activity against Aspergillus species, 
including A. fumigatus, which may impact the future management of 
patients with IA positively, specially CAPA [15]. 
Candida and candidiasis 
As covid-19 is still at a peak in some countries, secondary infections 
are rising too. The most fatal and superior of those are fungal 
infections. A frequent type of superficially occurring fungal infection 
among them is candidiasis [17]. Species of yeast that belong to the 
Candida genus include Candida albicans, Candida glabrata, Candida 
parapsilosis, Candida tropicalis, and Candida krusei, which are the 
most widespread fungal species inhabiting mucosal surfaces like 
skin, respiratory mucosa, digestive and urinary tracts too [18].  
Candida species are communion with humans and have virulence 
attributes too, enabling on which cause various infections in 
humans, especially when the immune system of the host is impaired 
[18]. Superficial infections associated with candidiasis are skin 
disorders, mucosal infections, Oropharyngeal or Vulvovaginitis 
Candidiasis, and Invasive Candidiasis [18]. Deep fungal infections 
occur by the proliferation of the pathogen in the deeper tissue area 
and are usually associated with ulceration and pricking of bony 
areas [17]. A patient with candidiasis has white patches/lesions 
mainly in the oral cavity (tongue, inner cheeks, and palate) said by 
experts from the national task force on covid-19, they further added 
that terming the candidiasis infection as the white fungus is 
incorrect and creating a link between them is a misnomer [19].  
Underlying diseases and cause  
Etiology  
Candidiasis is an opportunistic infection. Candida albicans, present 
in healthy persons, colonizes the oropharyngeal, esophageal, and 
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gastrointestinal mucosa. In an immunocompromised host, this 
species can cause mucosal candidiasis in the areas where they are 
usually present [18]. 
Patients with leukemia, lymphoma consumes corticosteroids and 
cytotoxic drugs which compromise their immunity and leading to 
candidiasis infection. Cancer chemotherapy may result in fungemia 
occurring due to Candida albicans, which develop from fungal 
translocation via compromised mucosal barriers [18]. Any changes 
in the host’s environment and the size or composition of 
endogenous bacterial population fungal infection of the upper and 
lower GIT transform into an opportunistic pathogen [18]. 
Fungal colonization in the vagina increases in Diabetes mellitus, 
pregnancy, and the use of oral contraceptives. Oral candidiasis is 
mostly associated with HIV patients, more than 90% of HIV patients 
show candidiasis. Others are TB, myxedema, hypoparathyroidism, 
Addison's disease, nutritional deficiency (vitamin A, B6, Iron), 
smoking, poorly maintained dentures, IV tubes, catheters, heart valves, 
old age, infancy, and pregnancy, Xerostomia too due to the absence of 
protective antifungal proteins, histatin, and calprotectin [18]. 
Epidemiology  
Infections related to Candida species have notably increased over the 
past few decades. Among this, one-third of invasive Candida infection is 
caused due to C. albicans [20]. Non-C. albicans species such as Candida 
glabrata (C. glabrata), Candida tropicalis (C. tropicalis), Candida 
parapsilosis (C. parapsilosis), and Candida krusei (C. krusei) have emerged 
now as secondary pathogen as pathogenic candidiasis in neonates [21].  
Among the Candida species, C. albicans was the most common 
species, followed by C. lusitaniae, C. parapsilosis, C. glabrata, C. kefyr, 
C. famata, C. africana, and C. orthopsilosis, respectively [18]. 
Pathophysiology  
When normal host immunity is disturbed, Candida albicans cause 
thrush. The Proliferation of organisms in oral mucosa causes 
epithelial cell desquamation and accumulation of keratin, bacteria, 
and necrotic tissue. This debris forms a pseudomembrane that 
closely adheres to the mucosa. This pseudomembrane may rarely 
involve extensive areas of edema, ulceration, and necrosis of the 
underlying mucosa [18]. 
Candida reaches the bloodstream by three major routes. The most 
frequent of these is via the GIT mucosal barrier, others through an 
intravascular catheter and form a localized infection. Candida can 
pass into the bloodstream in neutropenia patients as well as in 
intensive care unit patients too. Candida is also a part of the normal 
gut microflora, so any condition which makes a person 
immunocompromised can cause Invasive Candidiasis in the 
bloodstream. Candida growth in indwelling catheters in central 
lines, can occur either at the implantation site or at the hub and 
cause prevalence to the next Candida infection. Localized infection 
may not cause bloodstream invasion, but ascending Candida urinary 
tract infection associated with intrinsic obstruction or extrinsic 
compression may cause bloodstream invasion [18]. 
Vulvovaginal Candidiasis may occur with the use of local or systemic 
antimicrobial therapy and may cause precipitate recurrent episodes 
of the disease. Hypothetically, the pathophysiology of Vulvovaginal 
Candidiasis may be due to reduction or change in routine vaginal 
flora, yeast colonization, and proliferation [18]. 
Signs and symptoms  




Fig. 2: Explaining types of candidiasis and their symptoms 
 
Treatment and management  
The management of Invasive Candidiasis in both, covid-19 patients 
and the non-covid-19 patient is similar [21]. Patients with a 
localized burning sensation in the oral cavity are sometimes 
managed with an empiric anti candidiasis treatment. An empirical 
approach for oral candidiasis treatment is also preferred due to the 
increased cost of laboratory investigation of candidiasis. The culture 
investigation helps in quantifying candidiasis organisms and in 
differentiating between normal and increased levels of oral 
candidiasis infections [23]. Nystatin oral suspension for oral rinse is 
used in oral candidiasis, with guidance to patients to retain the 
suspension in the oral cavity before swallowing [23]. Oral 
applications of probiotics can be used as an adjuvant in the 
treatment of oral candidiasis [23]. Clotrimazole is used in 
Oropharyngeal Candidiasis treatment [23]. 
For Invasive Candidiasis, echinocandins are the choice of treatment, 
with fluconazole, Liposomal amphotericin B, voriconazole, 
posaconazole, and isavuconazole being the second line alternatives 
[21]. Fluconazole should be avoided in the first trimester of 
pregnancy [20]. Mild or moderate genital Candida infection can be 
treated with antifungal vaginal creams [21]. For recurrent vaginal 
Candida infections, fluconazole is prescribed [18]. The same is used 
for oral thrush too, with oral lozenges as a substitute [18]. 
Systemic Candidiasis is treated with oral or intravenous antifungal 
medications; including caspofungin, fluconazole, and amphotericin B 
[18]. Flucystine can be used in the treatment of systemic candidiasis 
[23].  
In denture-related candidiasis, the patient should be guided to 
microwave disinfection of acrylic-based dentures. This should be 
disinfected with chlorhexidine, hydrogen peroxide, and antifungal 
solutions [23]. 
Cryptococcus and cryptococcosis  
Cryptococcosis is potentially a deadly fungal infection commonly 
caused by inhalation of Cryptococcus neoformans or Cryptococcus 
gattii spores. Cases of covid-19 having shortness of breath are 
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mostly found to have associated pulmonary cryptococcosis. Serious 
cryptococcal infection occurs in immunocompromised patients but 
can also occur in immunocompetent adults [24]. A review study 
claims that the evolution of the HIV pandemic was an influence on 
the epidemiology of the cryptococcal disease. The same incidence of 
rising new infections that is prevalent in the covid era once at a peak 
in Africa during the HIV pandemic. Cryptococcosis lies at the third 
position of most common fungal infections after Candida and 
Aspergillus [25]. Earlier the link between fungal infection and covid-
19 was reported with Aspergillus species. But now, a few cases are 
available with co-infection with Cryptococcus too. Taking into 
account the fact that covid-19 causes ARDS, co-infection with 
Cryptococcus species nearly increases inflammation in the lung and 
the danger for poor results. Since corticosteroids are an important 
treatment in covid-19 with respiratory symptoms and hypoxemia, 
starting them in patients with cryptococcal infection should be 
strictly monitored for the chances of dissemination. An analyst 
should get cultures for Cryptococcus species from the blood and the 
central nervous system in covid-19 patients with pulmonary 
cryptococcosis and maintain the requirement for corticosteroids 
with the danger of cryptococcal dissemination [24]. 
covid-19 patients with human immunodeficiency virus (HIV) 
infection accompanied by CD4 T-lymphocyte count 200 cells/lL, 
Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT), 
SOT, or other immune impaired are sensitive to cryptococcosis, 
which is mostly present as meningoencephalitis. Given the 
difficulties adjoining the diagnosis of cryptococcosis and 
identification of Cryptococcus species, including C. neoformans and C. 
gattii species, the diagnosis of cryptococcosis is normally based on a 
combination of clinical and laboratory authentication. The methods 
employed to authenticate the infection are culture, direct 
microscopy, histopathology, serology, and molecular detection. To 
detect cryptococcosis, a sample of cerebrospinal fluid (CSF) can be 
combined with India ink and observed under a microscope that the 
characteristic structure of Cryptococcus species. With narrow 
budding encapsulated yeast usually can be found. Samples for 
culture should be given to Sabouraud dextrose agar at 30 degrees 
Celsius for 7 d, in aerobic conditions, and checked daily. Moreover, 
cultures from patients receiving systemic antifungal therapy may 
need a longer time to rise. Cryptococcus is visible as creamy mucoid 
colonies. Capsular polysaccharides of Cryptococcus can be defined 
and quantified from body fluids such as serum, CSF, BAL, or 
pathological tissue. Three formats of Cryptococcal Antigen (CrAg) 
identification tests are now available: the Latex Agglutination Test 
(LAT), the Enzyme-Linked Immunoassay (EIA), and the Lateral Flow 
Immunoassay (LFA). These methods are rapid, sensitive, and 
particular but have not been standardized for respiratory specimens 
such as BAL, pleural fluid, or sputum. Molecular detection of 
Cryptococcus is needed in particular situations where additional 
diagnostic tools have failed to authenticate the detection of 
cryptococcosis. These molecular methods include pan-fungal PCR, 
DNA sequencing for identification, multiplex PCR, isothermal 
amplification method, and probe-based microarrays. Once 
cryptococcosis is diagnosed, a lumbar puncture and cerebrospinal 
fluid (CSF) examination (including antigen) is suggested in all 
patients. Cryptococcus can spread into the central nervous system, 
causing cryptococcal meningitis. The treatment suggestions are as 
follows: (i) Induction phase for amphotericin B deoxycholate and 
flucytosine, followed by fluconazole; alternative options for 
fluconazole, flucytosine or amphotericin B deoxycholate, 
fluconazole. (ii) Consolidation phases for fluconazole. (iii) 
Maintenance (or secondary prophylaxis) phase for fluconazole [1]. 
 
 
Fig. 3: Diagnostic and therapeutic pathways for invasive fungal co-infections [1] what are fungal infections, named by colors. Black, white, 
yellow, cream, and green? 
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Fig. 4: Picture showing mucormycosis fungal infection in a person 
*Source-A covid care center  in Mandsaur , Madhya Pradesh, India 
 
Black fungus is caused by the order mucorale, in which the genus 
implicated is Rhizopus, Mucor. Black fungus has given this term so as 
it causes the invasion of tissues and blood vessels and thus 
interrupts the blood supply to the normal tissue, which gets then 




Fig. 5: Image shows the oral cavity affected by Candida albicans [27] 
 
White fungus is caused by a yeast (a type of fungus) called Candida. 
The most common species which cause the infection is Candida 
albicans [28]. White refers to the term Albicans. The white fungus 
has given this term as it grows in the lab as white spots on plates of 
agar and appears as white spots on the mucosa of the oral cavity 
[26]. Also, when it attacks private parts, there is a white color 




Fig. 6: Representational image of Aspergillus flavus [30] 
 
Yellow fungus belongs to the Aspergillus family. Most likely, it is 
Aspergillus flavus from the Aspergillus family. Flavus is the Greek 
word for yellow [30]. The yellow fungus has been given the term 
because of the yellow color pus it forms in the wounded area of a 




Fig. 7: Culture image of Cryptococcus gattii [31] 
Cryptococcus species form creamy mucoid layers when cultured in 
the laboratory and hence the name cream fungus. The species of 
Cryptococcus which cause co-fungal infection with covid-19 are 




Fig. 8: Culture Image of Aspergillus fumigatus [32] 
 
Green fungus is due to the Aspergillus family. The most prevalent 
cause of Aspergillus is Aspergillus fumigatus [33]. Green Fungus 
holds the term as the green color appears during its culture in the 
lab [34]. 
CONCLUSION 
The global pandemic has affected every country up to an extent. 
Maintaining public health along with the economic condition is a 
difficult task for a country, but the rising of Secondary infections in 
this condition makes the situation tougher. Fungal infections as 
raised secondary covid infections have increased the mortality rate 
of covid patients. In India, the cases of secondary fungal infections 
are higher than in any other country. The reason behind increased 
fungal infections is still unknown, but several studies claim that the 
extensive use of steroids in covid patients has a key role in 
compromising the immunity of the host and making him susceptible 
to fungal infections. Others include hospital environment, ventilation 
state, longer hospital stay, underlying diseases like Diabetes 
mellitus, and renal failure, increases the risk of fungal infections. 
Each type of fungal infection has its management of therapy and 
symptoms so early diagnosis is necessary for the early management 
of the disease. Early prevention in susceptible patients will help in 
disease management. Protocols for disease management and 
therapy will be beneficial in the management of fungal infections. 
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